尊敬的投资者各位好我是广州白云山医药集团股份有限公司董事总经理李虹下面由我为各位简要介绍一下广药白云山2023年及2024年一季度业绩的情况 公司成立于1997年,2013年6月完成换股吸收合并白云山A,并于同年7月正式更名为广州白云山医药集团股份有限公司,目前公司业务包括大染药、大健康、大商业、大医疗四大业务板块。 2023年,公司紧扣双效提升的发展主题,坚持稳中求进的总基调,从头抓好各项经营管理工作,全力促进运营效率和发展效益的提升,实现经营业绩的稳步增长。 2023年公司实现营业收入755.15亿元同比增长6.68%利润总额为51.1亿元同比增长1.33%归属本公司股东的净利润为40.56亿元同比增长2.25% 归属于本公司股东的扣除非经常性损益的净利润为36.36亿元同比上升9.53%经营活动产生的现金流金额为41.04亿元同比下降41.37%这主要是因为本公司下属子公司采购决算同比增加 2023年,公司大染药、大健康、大医疗及其他板块实现业绩的稳步增长,大商业板块业绩略有波动。 1、大莱药板块实现营业收入为108.89亿元同比增加4.09%毛利率为48.74%2、大健康板块实现营业收入为111.17 ...

广州白云山医药集团股份有限公司 关于子公司药用辅料通过共同审评的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 2024年5月15日，广州白云山医药集团股份有限公司（以下简称"公 司"）子公司广州白云山汉方现代药业有限公司（以下简称"白云山汉 方"）药用辅料蛋黄卵磷脂(供注射用)、油酸钠(供注射用)通过国家药 品监督管理局药品审评中心（以下简称"CDE"）共同审评。现将相关情 况公告如下： 一、药用辅料的基本情况 证券代码：600332 证券简称：白云山 公告编号：2024－030 1 （一）蛋黄卵磷脂(供注射用) 品种名称：蛋黄卵磷脂（供注射用） 登记号：F20200000313 包装规格：30g/袋、3kg/袋、5kg/袋 企业名称和地址：（1）名称：广州白云山汉方现代药业有限公司； （2）地址：广州市从化温泉大道8号 与制剂共同审评审批结果：A（A表示已批准在上市制剂使用的原料/ 辅料/包材） （二）油酸钠(供注射用) 品种名称：油酸钠(供注射用) 登记号：F20220000120 包装规格：100g/袋、500g ...

证券代码：600332 证券简称：白云山 公告编号：2024－028 广州白云山医药集团股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2024年5月16日(星期四)下午16:00-17:00 ● 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心视频和网络互动 ●投资者可于2024年5月9日(星期四) 至5月15日(星期三)16:00前登 录上证路演中心网站首页点击"提问预征集"栏目或通过本公司邮箱 sec@gybys.com.cn进行提问。本公司将在说明会上对投资者普遍关注的 问题进行回答。 广州白云山医药集团股份有限公司（以下简称"本公司"）已分别 于2024年3月16日、2024年4月27日发布本公司2023年年度报告以及2024 年一季度报告，为便于广大投资者更全面深入地 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2024年5月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 00874 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 | RMB | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 | RMB | | 1 RMB | | 219,900,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | ...

[Table_Title] 证券研究报告 24Q1 业绩稳健增长，推动高质量发展 公司研究 [Table_ReportDate] 2024年05月01日 [Table_ReportType] 公司点评报告 [T事ab件le：_白Su云mm山ar公y]司发布2024年第一季度报告，2024Q1公司实现营收229.46 [白Ta云bl山e_St（oc6k0A0n3dR3a2n.kS]H） 亿元（同比+6.09%），归母净利润19.58亿元（同比+2.59%），扣非归母 投资评级 无 净利润18.34亿元（同比+0.33%）。 点评： 上次评级 无 无  2023年和2024Q1业绩稳健增长。据公司公告，2023年公司实现营业 [唐Ta爱b金le_医Au药th行o业r]首席分析师 收入755.15亿元，同比增长6.68%，实现归母净利润40.56亿元，同 执业编号：S1500523080002 比增长2.25%，实现扣非归母净利润36.36亿元，同比增长9.53%。 联系电话：19328759065 从业务板块来看，2023年公司大南药营收108.91亿元（同比+4.09%）， 邮箱：tangaijin@cind ...

Financial Performance - The company's operating revenue for the first quarter reached RMB 22,946,212 thousand, representing a year-on-year increase of 6.09%[7] - Net profit attributable to shareholders was RMB 1,958,118 thousand, reflecting a growth of 2.59% compared to the same period last year[7] - Basic and diluted earnings per share were both RMB 1.204, marking a 2.59% increase from the previous year[7] - Total operating revenue for Q1 2024 reached RMB 22.95 billion, an increase of 6.1% compared to RMB 21.63 billion in Q1 2023[29] - Operating profit for Q1 2024 was RMB 2.45 billion, up from RMB 2.35 billion in Q1 2023, reflecting a growth of 4.2%[30] - Net profit attributable to shareholders for Q1 2024 was RMB 1.96 billion, compared to RMB 1.91 billion in Q1 2023, representing an increase of 2.5%[30] - Total comprehensive income for Q1 2024 reached approximately CNY 2.03 billion, a 3.57% increase from CNY 1.96 billion in Q1 2023[32] - Basic and diluted earnings per share for Q1 2024 were CNY 1.204, up from CNY 1.174 in Q1 2023, reflecting a growth of 2.55%[32] Cash Flow - The net cash flow from operating activities was negative at RMB (3,138,187) thousand, a decrease of 10.54% year-on-year[7] - Cash inflow from operating activities in Q1 2024 was approximately CNY 16.79 billion, compared to CNY 15.16 billion in Q1 2023, marking an increase of 10.73%[35] - Net cash flow from operating activities for Q1 2024 was negative CNY 3.14 billion, worsening from negative CNY 2.84 billion in Q1 2023[35] - Cash inflow from investment activities in Q1 2024 totaled CNY 75.78 million, a significant decrease of 73.32% from CNY 284.04 million in Q1 2023[36] - Net cash flow from investment activities was negative CNY 282.99 million in Q1 2024, improving from negative CNY 638.06 million in Q1 2023[36] - Cash inflow from financing activities in Q1 2024 was CNY 6.27 billion, slightly down from CNY 6.77 billion in Q1 2023, a decrease of 7.43%[36] - Net cash flow from financing activities increased to CNY 1.94 billion in Q1 2024, up from CNY 1.57 billion in Q1 2023, representing a growth of 23.36%[36] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 78,703,490 thousand, a slight increase of 0.15% from the end of the previous year[7] - Total liabilities decreased to RMB 39.99 billion as of March 31, 2024, down from RMB 41.91 billion as of December 31, 2023, a reduction of 4.6%[26] - Current liabilities totaled RMB 34.12 billion, a decrease of 5.8% from RMB 36.24 billion at the end of 2023[26] - Non-current liabilities increased to RMB 5.87 billion, up from RMB 5.67 billion, marking a growth of 3.6%[26] - Total equity attributable to shareholders rose to RMB 36.88 billion, an increase of 5.6% from RMB 34.92 billion at the end of 2023[27] Assets Composition - As of March 31, 2024, the total current assets amounted to RMB 55,959,814,735.97, slightly down from RMB 55,983,713,725.09 as of December 31, 2023[23] - The total non-current assets increased to RMB 22,743,675,532.53 from RMB 22,603,164,039.00, indicating a growth in long-term investments[24] - Cash and cash equivalents decreased to RMB 19,754,460,865.10 from RMB 21,308,844,204.44, showing a decline of approximately 7.3%[23] - Accounts receivable rose to RMB 16,715,572,929.90 from RMB 15,112,494,798.69, representing an increase of about 10.6%[23] - The inventory decreased to RMB 9,848,755,918.40 from RMB 11,507,099,742.41, indicating a reduction of approximately 14.4%[23] Other Financial Information - Non-recurring gains and losses for the period totaled RMB 124,577 thousand, after accounting for tax and minority interests[13] - The company received government subsidies amounting to RMB 96,378 thousand during the reporting period[10] - The weighted average return on net assets was 5.45%, a decrease of 0.33 percentage points compared to the previous year[7] - The company did not conduct an audit for the first quarter financial statements[5] - Research and development expenses for Q1 2024 were RMB 186.14 million, slightly higher than RMB 179.39 million in Q1 2023, indicating a focus on innovation[29] - The company reported a tax expense of RMB 420.62 million for Q1 2024, compared to RMB 385.93 million in Q1 2023, reflecting an increase of 9.0%[30] - Other comprehensive income after tax for Q1 2024 was RMB 1.51 million, recovering from a loss of RMB 5.96 million in Q1 2023[30] - The impact of exchange rate changes on cash and cash equivalents was an increase of CNY 2.43 million in Q1 2024, compared to an increase of CNY 1.80 million in Q1 2023[37] Shareholder Information - The total equity attributable to shareholders is not explicitly mentioned but is implied to be stable given the slight changes in total assets and liabilities[24] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[21] - The company has not reported any participation in margin financing or securities lending activities by the top shareholders[21] - There are no significant new strategies or product developments mentioned in the provided documents[22]

本议案已经本公司 2024 年第 2 次审核委员会会议审议通过。 2、关于续聘大信会计师事务所（特殊普通合伙）为本公司 2024 年年度财 务审计机构的议案（有关内容详见公司日期为 2024 年 4 月 26 日、编号为 2024 -026 的公告） 表决结果：同意票 11 票、反对票 0 票、弃权票 0 票，审议通过本议案。 证券代码：600332 证券简称：白云山 公告编号：2024－025 广州白云山医药集团股份有限公司 第九届董事会第十次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内 容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（以下简称"本公司"）第九届董事会第 十次会议（以下简称"会议"）于 2024 年 4 月 12 日以电邮方式发出通知，于 2 024 年 4 月 26 日以通讯形式召开。本次会议应参加表决董事 11 人，实际参加表 决董事 11 人。会议的召集、召开符合《公司法》及《公司章程》的规定。 经董事审议、表决，会议审议通过如下议案： 1、本公司 2024 年第一季度报告 表决结果：同意票 11 票、 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 22,946,212, representing a year-on-year increase of 6.09%[4] - The net profit attributable to shareholders for the same period was CNY 1,958,118, reflecting a growth of 2.59% compared to the previous year[4] - Basic and diluted earnings per share for Q1 2024 were both CNY 1.204, an increase of 2.59% from the same period last year[5] - Total operating revenue for Q1 2024 reached CNY 22,946,211,891.84, an increase of 6.1% compared to CNY 21,628,521,022.04 in Q1 2023[19] - Net profit for Q1 2024 was CNY 2,031,724,927.91, compared to CNY 1,969,054,925.32 in Q1 2023, representing a growth of 3.2%[21] - The company reported a total comprehensive income of CNY 2,033,231,749.61 for Q1 2024, compared to CNY 1,963,092,974.12 in Q1 2023[21] Cash Flow - The net cash flow from operating activities was negative at CNY (3,138,187), a decline of 10.54% year-on-year[4] - In Q1 2024, the company reported cash inflows from operating activities totaling CNY 16,789,987,378.48, an increase from CNY 15,161,136,193.40 in Q1 2023, representing a growth of approximately 10.7%[23] - The net cash outflow from operating activities was CNY (3,138,186,616.77), compared to CNY (2,838,882,221.33) in the same period last year, indicating a decline in operational cash flow[23] - Investment activities generated a net cash outflow of CNY (282,996,800.88) in Q1 2024, a decrease from CNY (638,055,604.71) in Q1 2023, reflecting improved cash management in investments[25] - The net cash flow from financing activities was CNY 1,939,655,468.86, compared to CNY 1,571,436,553.79 in the previous year, indicating a positive trend in financing[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 78,703,490, a slight increase of 0.15% from the end of the previous year[5] - Current assets totaled ¥55,959,814,735.97, showing a marginal decrease from ¥55,983,713,725.09[16] - Total liabilities as of Q1 2024 were CNY 39,990,236,195.46, a decrease from CNY 41,909,053,857.29 in the previous year[20] - The total non-current liabilities amounted to CNY 5,870,219,387.47, an increase from CNY 5,673,763,356.34 in the previous year[20] Shareholder Information - The total equity attributable to shareholders increased to CNY 36,878,108, up 5.61% from the previous year[5] - The number of ordinary shareholders at the end of the reporting period was 92,562[8] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., held 45.04% of the shares[9] Expenses - Total operating costs for Q1 2024 were CNY 20,666,670,426.99, up from CNY 19,332,774,093.08 in Q1 2023, reflecting a year-over-year increase of 6.9%[20] - Research and development expenses for Q1 2024 amounted to CNY 186,139,000.55, compared to CNY 179,389,510.16 in Q1 2023, indicating a rise of 3.9%[20] - The company paid CNY 1,744,322,516.63 in employee compensation during Q1 2024, compared to CNY 1,665,413,999.81 in Q1 2023, reflecting a 4.7% increase in labor costs[23] - The company’s tax payments amounted to CNY 832,382,327.22 in Q1 2024, down from CNY 1,006,065,170.89 in the same period last year, suggesting improved tax efficiency[23]

通知书编号：2024B01785 受理号：CYHB2350211 证券代码：600332 证券简称：白云山 公告编号：2024－027 广州白云山医药集团股份有限公司 关于子公司获得药品补充申请批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"）全 资子公司广州白云山明兴制药有限公司（以下简称"明兴药业"） 收到国 家药品监督管理局（以下简称"国家药监局"）签发的《药品补充申请批 准通知书》，盐酸多巴胺注射液已按质量与疗效一致性评价申报途径进行 补充申请，从而获得国家药监局批准变更相关内容。现将有关情况公告如 下： 一、药品的基本情况 药品名称：盐酸多巴胺注射液 剂型：注射剂 规格：2ml:20mg 注册分类：化学药品 上市许可持有人名称：广州白云山明兴制药有限公司，地址：广州市 海珠区工业大道北 48 号 1 生产企业：广州白云山明兴制药有限公司，地址：广州市海珠区工业 大道北 48 号 原药品批准文号：国药准字 H44022388 申请内容：申报仿制药质量与 ...

证券代码：600332 证券简称：白云山 公告编号：2024－026 广州白云山医药集团股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●拟聘任的会计师事务所名称：大信会计师事务所（特殊普通合伙） 2022 年度业务收入 15.78 亿元（人民币，下同），为超过 10,000 家 公司提供服务。业务收入中，审计业务收入 13.65 亿元、证券业务收入 5.10 亿元。2022 年上市公司年报审计客户 196 家（含 H 股），平均资产 1 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 大信会计师事务所（特殊普通合伙）（以下简称"大信"）成立于 1985 年，2012 年 3 月转制为特殊普通合伙制事务所，总部位于北京，注册地 址为北京市海淀区知春路 1 号 22 层 2206。大信在全国设有 32 家分支机 构，在香港设立了分所，并于 2017 年发起设立了大信国际会计网络，目 前拥有美国、加拿大、澳大利亚、德国、法国、英国、新加坡等 38 家网 络成 ...